Nov 3, 2022 Syros Pharmaceuticals to Present Initial Data from SELECT-AML-1 Phase 2 Trial at 64th ASH Annual Meeting
Sep 16, 2022 Syros Announces Closing of Merger with Tyme Technologies and Concurrent Private Placement
Sep 13, 2022 Syros Receives FDA Orphan Drug Designation for SY-5609 for the Treatment of Pancreatic Cancer
Aug 3, 2022 Syros Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Tamibarotene for the Treatment of MDS
